Elekta AB (ADR) (OTC:EKTAY) Receives a Downgrade
In a recent research report revealed to clients on 8 December, Morgan Stanley has decided to cut rating on Elekta AB (ADR) (OTC:EKTAY) shares to a “Underweight”. EKTAY’s prior rating was a “Equal-weight”.
The stock decreased 3.01% or $0.26 on December 8, striking $8.39. Approximately shares of stock traded hands. ELEKTA UNSP ADR EACH REPR 1 ORD (OTC:EKTAY) has declined 10.36% since May 6, 2015 and is downtrending. It has underperformed by 9.57% the S&P500.
According to Zacks Investment Research, “Elekta AB is a human care company engaged in developing and selling clinical solutions for the treatment of cancer and neurological diseases. It develops tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. The Company’s offering is divided into five areas: Neuroscience, Oncology, Software, Brachytherapy and Services. Elekta AB is headquartered in Stockholm, Sweden.” Get a free copy of the Zacks research report on ELEKTA UNSP ADR EACH REPR 1 ORD (EKTAY).